Search the evidence register: research titles, expert names and patent numbers

review · 2024

Systematic reviews: MSC for knee osteoarthritis

Multiple institutions (indexed in PubMed)

Multiple studies report short- to medium-term improvement in pain and function; evidence of cartilage regeneration remains limited and methods vary widely.

phase1-2 · 2025

MSC clinical trials in newly diagnosed type 1 diabetes

International trial registries

Primary endpoints are safety; some studies report more stable insulin requirement and C-peptide over short follow-up, with no conclusions on long-term effect.

phase1-2 · 2025

iPSC-derived dopaminergic neuron transplantation in Parkinson's disease

Specialised research centres in Japan and the United States

Reports procedural safety and graft survival in small numbers of participants; motor outcomes require long-term follow-up.

phase2 · 2024

MSC administration in decompensated liver cirrhosis

Multiple institutions (indexed in PubMed)

Some studies report improved albumin and MELD scores over 6–12 months; results are inconsistent between studies and standard care is unchanged.

review · 2023

Meta-analyses: cell therapy after myocardial infarction

Multiple institutions (indexed in PubMed)

Effects on ejection fraction are small and inconsistent, with no clear mortality benefit in large trials.

phase1-2 · 2024

Intravenous MSC in COPD

International trial registries

Reported as well tolerated short term with reductions in some inflammatory markers; no confirmed significant change in lung function.

phase2 · 2025

MSC in autoimmune disease: research overview

Multiple institutions (indexed in PubMed)

The most advanced research is in graft-versus-host disease, lupus nephritis and fistulising Crohn's disease. Where products are approved, indications are very narrow.

phase1-2 · 2024

MSC and cell secretome in atopic dermatitis

Multiple institutions (indexed in PubMed)

Small studies report reduced severity scores in some patients; better-controlled studies are needed for confirmation.

phase1 · 2024

MSC in chronic kidney disease: early studies

International trial registries

Focused on safety and eGFR decline in small numbers of participants; no evidence of nephron regeneration.

review · 2026

EHL BIO patents and research papers

EHL BIO (Republic of Korea)

EHL BIO publishes a list of patents and research papers in the R&D section of its corporate website. Readers should verify the current list at the source before citing.

review · 2026

EHL BIO GMP cell manufacturing centre

EHL BIO (Republic of Korea)

Company public information describes the manufacturing centre, quality systems and cell handling processes. Certifications and current status should be verified at the source.

phase3 · 2025

AHSCT in treatment-refractory relapsing multiple sclerosis

Multiple specialist transplant centres (indexed in PubMed)

Comparative studies report reduced relapse rates in strictly selected patients, at the cost of high-dose chemotherapy risk; specialist centres only.

19 Nov 2016

Human adipose tissue derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation

6 Nov 2018

Human Adipose Tissue Derived Mesenchymal Stem Cells Attenuate Atopic Dermatitis by Regulating the Expression of MIP2, miR122a-SOCS1 Axis, and Th1/Th2 Responses

30 Apr 2022

Urine-Derived Stem Cell-Secreted Klotho Plays a Crucial Role in the HK-2 Fibrosis Model by Inhibiting the TGF-β Signaling Pathway

21 Dec 2022

Production enhancement of human adipose-derived mesenchymal stem cells by low-intensity ultrasound stimulation

10 Dec 2023

In vivo safety and biodistribution profile of Klotho-enhanced human urine-derived stem cells for clinical application

18 Jan 2024

Combinational Pulsing of TAAs Enforces Dendritic Cell-Based Immunotherapy through T-Cell Proliferation and Interferon-γ Secretion in LLC1 Mouse Model

No. 10-1172638

Novel thiazolidinedione derivatives and uses thereof

Registered 2 Aug 2012

States activity inhibiting 15-PGDH, which breaks down prostaglandin, so it may be used to prevent or treat cardiovascular, gastrointestinal and kidney disease, and to prevent hair loss and promote hair growth (as described in the patent).

No. 15771853

Composition comprising cells treated with a 15-PGDH inhibitor or culture thereof and use thereof

Registered 27 Oct 2016

No. 10-2016-0007049

Liposuction and SVF separation kit

Registered 20 Jan 2016

Intended to facilitate fat collection and the series of processes for separating adipose-derived stem cells.

No. 10-2016-0139967

Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

Registered 26 Oct 2016

Pharmaceutical composition for preventing or treating atopic disease, using cells cultured with a 15-PGDH inhibitor in PGE2-expressing cells or their culture (atopic dermatitis).

No. 10-2018-0001149

Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

Registered 4 Jan 2018

Same family of pharmaceutical composition, with the indication stated as rheumatoid arthritis.

No. 10-2018-0030906

Compositions and uses comprising cells treated with 15-PGDH inhibitors or cultures thereof

Registered 16 Mar 2018

Pharmaceutical composition for preventing or treating atopic disease (atopic dermatitis).

Number not stated

Method for mass culturing adipose-derived stem cells expressing FoxO

Registered 28 Dec 2018

Related to a composition comprising cells treated with a 15-PGDH inhibitor or their culture and its use.

No. 10-2019-0139702

Medium composition for culturing urine-derived stem cells and method for culturing them

Registered 4 Nov 2019

Culture medium for isolating and culturing urine-derived stem cells, and a method for separating and culturing them using that medium.

No. 10-2020-0012437

Mass culture method of adipose-derived stem cells expressing anti-ageing factors

Registered 3 Feb 2020

Mass culture method for adipose-derived stem cells expressing Foxo1, Foxo3a and Klotho, with a medium composition for their proliferation and culture.

No. 10-2021-0021026

Composition for skin regeneration, whitening, antioxidant or wound treatment comprising stem cell-derived exosomes

Registered 17 Feb 2021

Cosmetic or pharmaceutical composition with urine-derived stem cell exosomes as the active ingredient.

No. 10-2021-0129299

Medium composition and method for isolating and culturing urine-derived stem cells with improved renal-disease function, and a cell therapeutic composition

Registered 29 Sept 2021

Covers the culture medium, the isolation and culture method, the resulting cells, and a cell therapeutic composition comprising them.

EHL BIO

MD Hong-gi Lee (CEO)

Chief Executive Officer, EHLBIO Co., Ltd.

Direction of stem cell, immune cell and exosome therapeutics development

EHL BIO

EHL BIO Stem Cell Research Institute

Stem cell therapeutics research and development team

ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes

EHL BIO

EHL BIO GMP Centre Quality Team

Manufacturing, quality control and cell banking

Class 100 clean facilities, cell banking systems and pre/post-cryopreservation quality control

EHL BIO

EHL BIO Immune Cell Research Team

Immune cell therapy research and immune cell banking

Keycell-IM programme (T, NK, iNKT and dendritic cells); the hospital's affiliated research centre states lung cancer as the preclinical target

EHL Thailand

EHL Thailand Medical Information Team

Writes and reviews disease pages and stem cell topics

Evidence levels, regulatory status, and separating hospital information from medical information

EHL Thailand

EHL Thailand Research Desk

Reviews articles, research summaries and clinical trial status

Careful reading of study results, including sample size, trial phase and limitations